Immunological Aspects of Malignant Gliomas

Canadian Journal of Neurological Sciences

Volumn 43, Issue 4, 2016, Pages 494-502

  Cohen Inbar, Or ^a,b,c,d   Zaaroor, Menashe ^a,b,c  

^a Rambam Health Care Center   (Israel)

^b Molecular Medicine Laboratory   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anergy; Astrocytromas; Checkpoint inhibitors; Cytokine Modulation; Dendritic Cell vaccination; Glioblatoma Multiforma; Glioma; Immuno Resistance; Immunotherapy; Neuro oncology Surgical; Neuroimmunology

Indexed keywords

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); GLIOBLASTOMA; HUMAN; KNOWLEDGE; MELANOMA; PRIORITY JOURNAL; SYNAPSE; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY;

EID: 84975743877     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2016.34     Document Type: Article

References (98)

1. Mao YM, Desmeules M, Semenciw RM, Hill G, Gaudette L, Wigle DT. Increasing brain cancer rates in Canada. CMAJ. 1991;145:1583-91.
2. Karsy M. Mechanisms of gliomagenesis and glioblastoma multiforme variants. Folia Neuropathol. 2012;50:301-21.
3. Habberstad AH, Lind-Landström T, Sundstrøm S, Torp SH. Primary human glioblastomas-prognostic value of clinical and histopathological parameters. Clin Neuropathol. 2012;31:361-8.
4. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10-4.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
6. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-23.
7. Chaichana KL, Zaidi H, Pendleton C, et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res. 2011;33:759-64.
8. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110:583-8.
9. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012;23: 307-22.
10. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;s15:e395-403.
11. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015, Sep;11(9):504-14.
12. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-93.
13. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 anti-body for metastatic melanoma. Clin Cancer Res. 2011;17:6958-62.
14. Patel MA, Pardoll DM. Concepts of immunotherapy for glioma. J Neurooncol. 2015;123:323-30.
15. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000;343:702-9.
16. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-34.
17. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature. 2002;419:845-9.
18. Stefanova I, Dorfman JR, Germain RN. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature. 2002;420:429-34.
19. Davis MM, Krogsgaard M, Huppa JB, et al. Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem. 2003;72:717-42.
20. Walker PR, Calzascia T, Dietrich PY. All in the head: obstacles for immune rejection of brain tumours. Immunology. 2002;107:28-38.
21. Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis. Curr Opin Neurol. 2001;14:299-304.
22. Dörries R. The role of T-cell-mediated mechanisms in virus infections of the nervous system. Curr Top Microbiol Immunol. 2001;253:219-45.
23. Fischer HG, Bonifas U, Reichmann G. Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol. 2000;164:4826-34.
24. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11-28.
25. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292-302.
26. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents. Oncogene. 2007;26:3714-33.
27. Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol. 2000;78:179-95.
28. Princiotta MF, Finzi D, Qian SB, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing, Immunity. 2003;18:343-54.
29. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64:4980-6.
30. Zhang JG, Eguchi J, Kruse CA, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007;13:566-75.
31. Saikali S, Avril T, Collet B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 2007;81:139-48.
32. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003;63:8487-91.
33. Silbergeld DL, Rostomily RC, Alvord EC Jr. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsyfindings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol. 1991;10:179-85.
34. Aghi MK, Batchelor TT, Louis DN, Barker FG, Curry WT Jr. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol. 2009;93:115-20.
35. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84-8.
36. Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 2002;103:171-8.
37. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-302.
38. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncol. 2006;8:234-43.
39. See AP, Parker JJ, Waziri A. The role of regulatory T cells and microglia in Glioblastoma-associated immunosuppression. J Neurooncol. 2015;123:405-12.
40. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742-6.
41. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 2002;8:1100-6.
42. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol. 2001;159:779-86.
43. Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control. 2003;10:138-47.
44. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol. 2007;17:469-79.
45. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol. 2003;13:343-51.
46. Das A, Tan WL, Teo J, Smith DR. Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol. 2002;128:302-6.
47. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10:133-46.
48. Zisakis A, Piperi C, Themistocleous MS, et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine. 2007;39:99-105.
49. Yamanaka R. Dendritic-cell-and peptide-based vaccination strategies for glioma, Neurosurg Rev. 2009;32:265-73.
50. Muragaki Y, Maruyama T, Iseki H, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma: clinical article. J Neurosurg. 2011;115:248-55.
51. Palu G, Cavaggioni A, Calvi P, et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 1999;6:330-7.
52. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988;62:665-71.
53. Parsa A, Crane C, Wilson S, et al. Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy. In Proceedings of the AACE-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 2007.
54. Ampie L, Choy W, Lamano JB, Fakurnejad S, Bloch O, Parsa AT. Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol. 2015;123:441-8.
55. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
56. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33.
57. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-9.
58. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430-7.
59. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-65.
60. Opdivo (nivolumab) [prescribing information] http://www.opdivo. bmscustomer connect.com/gateway (Bristol-Myers Squibb Company, 2014).
61. Keytruda (pembrolizumab) [prescribing information] http://www. merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf (Merck & Co., Inc. 2015).
62. Krauze AV, Myrehaug SD, Chang MG, et al. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92:986-92.
63. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290-301.
64. Castro MG, Baker GJ, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clin Cancer Res. 2014;20:5147-9.
65. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002;62:5835-44.
66. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci. 2002;99:9421-6.
67. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol. 2003;170: 4349-4361.
68. Denkberg G, Klechevsky E, Reiter Y. Modification of a tumorderived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCRlike recombinant antibodies. J Immunol. 2002;169:4399-407.
69. Cohen-Inbar O. Recruitment of Immune Effector Cells against Astrocytoma by MHC-chlrotoxin Chimeric Protein. PhD dissertation, Technion Israel Institute of Technology, 2014.
70. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell in-filtration. Cancer Res. 2001;61:842-7.
71. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic andintracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-25.
72. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722-9.
73. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neuro-Oncol. 2001;53:39-46.
74. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004;22:4272-81.
75. Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for Glioblastoma multiforme patients. Cancer Sci. 2007;98:1226-33.
76. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for highgrade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncol. 2011;13:132-42.
77. Merchant RE, McVicar DW, Merchant LH, Young HF. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-? . Results of a phase I clinical trial. J Neuro-Oncol. 1992;12:75-83.
78. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurgery. 1989;70:175-82.
79. Colombo F, Barzon L, Franchin E, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 2005;12: 835-48.
80. Farkkila M, Jaaskelainen J, Kallio M, et al. Randomised, controlled study of intratumoral recombinant ?-interferon treatment in newly diagnosed glioblastoma. Br J Cancer. 1994;70:138-41.
81. Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neuro-Oncol. 2006;79:315-21.
82. Allen J, Packer R, Bleyer A, Zeltzer P, Prados M, Nirenberg A. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol. 1991;9:783-8.
83. Fetell MR, Housepian EM, Oster MW, et al. Intratumor administration of beta-interferon in recurrent malignant gliomas. A Phase I clinical and laboratory study. Cancer. 1990;65:78-83.
84. Mahaley MS, Dropcho EJ, Bertsch L, Tirey T, Gillespie GY. Systemic beta-interferon therapy for recurrent gliomas: a brief report. J Neurosurgery. 1989;71:639-41.
85. Buckner JC, Brown LD, Kugler JW, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurgery. 1995;82:430-5.
86. Buckner JC, Schomberg PJ, McGinnis WL, et al. A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001;92:420-33.
87. Olson JJ, McKenzie E, Skurski-Martin M, Zhang Z, Brat D, Phuphanich S. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neuro-Oncol. 2008;90:293-9.
88. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67.
89. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with highgrade glioma. Clin Cancer Res. 2000;6:2157-65.
90. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004;27:452-9.
91. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46:2101-4.
92. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 1991;28:16-23.
93. Hayes RL, Koslow M, Hiesiger EM, et al. Improved long term survival after intracavitary interleukin-2 and lymphokineactivated killer cells for adults with recurrent malignant glioma. Cancer. 1995;76:840-52.
94. Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27: 398-404.
95. Tsurushima H, Liu SQ, Tuboi K, et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jap J Cancer Res. 1999;90:536-45.
96. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6:2209-18.
97. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment. Clin Dev Immunol. 2011;2011:732413, doi: 10.1155/2011/732413. Epub 2011 Dec 10.
98. Caruso JP, Cohen-Inbar O, Bilsky MH, Gerszten PC, Sheehan JP. Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. Neurosurg Focus. 2015;38:E6.